11.08.2023 14:55:34

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

Bagsværd, Denmark, 11 August 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

Please find below a statement of such trading in shares issued by Novo Nordisk.

1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonKasim Kutay
2 Reason for the notification
a)Position/statusMember of the Board of Directors
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
ADRs

 Identification codeNVO
b)Nature of the transactionSale of ADRs
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 1,253.48276 ADRs 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


276 ADRs
DKK 1,253.48
e)Date of the transaction2023-08-10
f)Place of the transactionNew York Stock Exchange


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaha Kutay
2 Reason for the notification
a)Position/statusClosely related to Kasim Kutay, member of the Board of Directors
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 1,230.451,396 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


1,396 shares
DKK 1,230.45
e)Date of the transaction2023-08-10
f)Place of the transactionNasdaq Copenhagen


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonMaziar Mike Doustdar
2 Reason for the notification
a)Position/statusExecutive Vice President, head of International Operations
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 1,241.885,321 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


5,321 shares
DKK 1,241.88
e)Date of the transaction2023-08-10
f)Place of the transactionNasdaq Copenhagen


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonLudovic Helfgott
2 Reason for the notification
a)Position/statusExecutive Vice President, head of Rare Disease
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 1,242.366,432 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


6,432 shares
DKK 1,242.36
e)Date of the transaction2023-08-10
f)Place of the transactionNasdaq Copenhagen


1 Details of the person discharging managerial responsibilities/person closely associated
a)Name of the Board member/Executive/Associated PersonCamilla Sylvest
2 Reason for the notification
a)Position/statusExecutive Vice President, head of Commercial Strategy and Corporate Affairs
b)Initial notification/AmendmentInitial notification
3 Details of the issuer
a)NameNovo Nordisk A/S
b)LEI549300DAQ1CVT6CXN342
4 Details of the transaction(s)
a)Description of the financial instrument,
type of instrument,
Shares

 Identification codeNovo Nordisk B DK0060534915
b)Nature of the transactionSale of shares
c)







Price(s) and volume(s)







    
 Price(s)Volume(s) 
 DKK 1,238.5210,000 shares 
    
    
d)Aggregated information
  • Aggregated volume
  • Price


10,000 shares
DKK 1,238.52
e)Date of the transaction2023-08-10
f)Place of the transactionNasdaq Copenhagen

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 59,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media: 
Ambre James-Brown
+45 3079 9289
abmo@novonordisk.com

Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com

Investors: 
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com

Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com

David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com

Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com

Sina Meyer
+45 3075 6656 azey@novonordisk.com

Frederik Taylor Pitter
+45 3075 8259 fptr@novonordisk.com

Company announcement No 53 / 2023

Attachment


Analysen zu Novo Nordiskmehr Analysen

29.04.24 Novo Nordisk Neutral UBS AG
25.04.24 Novo Nordisk Overweight JP Morgan Chase & Co.
24.04.24 Novo Nordisk Outperform Bernstein Research
26.03.24 Novo Nordisk Neutral UBS AG
25.03.24 Novo Nordisk Overweight Barclays Capital
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!